For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Vera Therapeutics Inc (NASDAQ: VERA) was $1.71M for the day, up 1335059% from the previous closing price of $20.92. In other words, the price has increased by $1335059 from its previous closing price. On the day, 1.34 million shares were traded. VERA stock price reached its highest trading level at $21.13 during the session, while it also had its lowest trading level at $20.53.
Ratios:
Our analysis of VERA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 27.30 and its Current Ratio is at 27.30. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.
On January 28, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $58.Goldman initiated its Buy rating on January 28, 2025, with a $58 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 21 ’25 when Fordyce Marshall sold 10,613 shares for $27.89 per share. The transaction valued at 296,032 led to the insider holds 213,740 shares of the business.
Fordyce Marshall sold 9,075 shares of VERA for $250,882 on Feb 26 ’25. The PRESIDENT AND CEO now owns 204,665 shares after completing the transaction at $27.65 per share. On Feb 26 ’25, another insider, MARSHALL FORDYCE, who serves as the Director of the company, bought 9,075 shares for $27.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERA now has a Market Capitalization of 1330329856 and an Enterprise Value of 794959936.
Stock Price History:
The Beta on a monthly basis for VERA is 1.13, which has changed by -0.40212095 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -7.59%, while the 200-Day Moving Average is calculated to be -38.94%.
Shares Statistics:
VERA traded an average of 1.71M shares per day over the past three months and 2685060 shares per day over the past ten days. A total of 63.77M shares are outstanding, with a floating share count of 45.88M. Insiders hold about 28.26% of the company’s shares, while institutions hold 90.09% stake in the company. Shares short for VERA as of 1748563200 were 8947513 with a Short Ratio of 5.22, compared to 1745971200 on 5958240. Therefore, it implies a Short% of Shares Outstanding of 8947513 and a Short% of Float of 16.17.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Vera Therapeutics Inc (VERA) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.81, with high estimates of -$0.66 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.79 and -$3.86 for the fiscal current year, implying an average EPS of -$3.3. EPS for the following year is -$3.02, with 6.0 analysts recommending between -$2.28 and -$3.72.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $37.28M in the next fiscal year. The high estimate is $81.7M and the low estimate is $2.57M.
